Psychosocial interventions for people with both severe mental illness and substance misuse

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 12, 2019, Pages

  Hunt, Glenn E ^a   Siegfried, Nandi ^b   Morley, Kirsten ^a   Brooke Sumner, Carrie ^b   Cleary, Michelle ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION SEVERITY INDEX; ALCOHOL AND DRUG USE DISORDERS SECTION OF THE STRUCTURED CLINICAL INTERVIEW FOR DSM III R; ALCOHOL CONSUMPTION; ALCOHOL USE DISORDERS IDENTIFICATION TEST; ALCOHOL USE INVENTORY; ALCOHOL USE SCALE; ATTITUDE ASSESSMENT; BECK DEPRESSION INVENTORY; BEHAVIOR DISORDER ASSESSMENT; BRIEF PSYCHIATRIC RATING SCALE; BRIEF QUALITY OF LIFE SCALE; BRIEF SYMPTOM INVENTORY; CANNABIS AND SUBSTANCE USE ASSESSMENT SCHEDULE; CANNABIS USE; CLIENT SATISFACTION QUESTIONAIRE; CLINICAL OUTCOME; COGNITION ASSESSMENT; COGNITIVE BEHAVIORAL THERAPY; COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE; CONTINGENCY MANAGEMENT; DEATH; DISEASE SEVERITY; DRUG USE SCALE; ECONOMIC ASPECT; EDUCATION; FUNCTIONAL ASSESSMENT; GLOBAL ASSESSMENT OF FUNCTIONING; HEALTH CARE MANAGEMENT; HEALTH OF THE OUTCOME NATION OUTCOMES SCALE; HOMELESSNESS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HOSPITAL READMISSION; HUMAN; INSIGHT SCALE; INTEGRATED HEALTH CARE SYSTEM; INTERMETHOD COMPARISON; LIFE SATISFACTION; MENTAL DISEASE; MENTAL DISEASE ASSESSMENT; MOTIVATIONAL INTERVIEWING; OPIATE TREATMENT INDEX; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PRISON; PSYCHOSOCIAL CARE; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUALITY OF LIFE INTERVIEW; RELAPSE; REVIEW; ROLE FUNCTIONING SCALE; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SERVICE UTILIZATION RATING SCALE; SKILLS TRAINING; SOCIAL ADJUSTMENT SCALE FOR THE SEVERELY MENTALLY ILL; SOCIAL AND OCCUPATIONAL FUNCTIONING SCALE; SOCIAL FUNCTIONING SCALE; SOCIAL INTERACTION; SUBSTANCE ABUSE; SUBSTANCE ABUSE TREATMENT SCALE; SUBSTANCE USE SEVERITY SCALE; SYMPTOM CHECKLIST 90; SYSTEMATIC REVIEW; THERAPY EFFECT; WORLD HEALTH ORGANIZATION QUALITY OF LIFE SCALE; DRUG DEPENDENCE; HOSPITALIZATION; META ANALYSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE;

COGNITIVE BEHAVIORAL THERAPY; HOSPITALIZATION; HUMANS; MENTAL DISORDERS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SUBSTANCE-RELATED DISORDERS;

EID: 85076477961     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001088.pub4     Document Type: Review

References (454)

1. Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, et al. Evaluation of a motivational interview for substance use within psychiatric inpatient services. Addiction 2002;97(10):1329-38. [CSzG: 8308]x-wiley/crsRef/2704906
2. Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, et al. Motivational interviewing among psychiatric inpatients with substance use disorders. Acta Psychiatrica Scandinavica 2002;106(3):233-40. [CSzG: 16812]x-wiley/crsRef/2704907
3. Baker A, Bucci S, Kay-Lambkin F. Intervention for alcohol, cannabis and amphetamine use among people with a psychotic illness. NDARC Technical Report No. 193. Sydney: National Drug and Alcohol Research Centre, 2004:1-100. [CSzG: 16861; ISBN:1 887027 84 7]x-wiley/crsRef/2704909
4. Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders - Randomised controlled trial. British Journal of Psychiatry 2006;188(5):439-48. [CSzG: 13856]x-wiley/crsRef/2704910
5. Baker A, Bucci S, Lewin TJ, Richmond R, Carr VJ. Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. Psychiatry Research 2005;134(3):241-50. [CSzG: 16810]x-wiley/crsRef/2704911
6. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry 2001;158(10):1706-13. [CSzG: 7863]x-wiley/crsRef/2704913
7. Haddock G. Dual diagnosis project: evaluation of family support and cognitive behaviour therapy for recent onset schizophrenia sufferers with substance misuse problems. National Research Register 2001; Vol. 1. [CSzG: 5489; N0244032344]x-wiley/crsRef/2704915
8. Haddock G, Barrowclough C, Tarrier N, Moring J, O'Brien R, Schofield N, et al. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry 2003;183(November):418-26. [CSzG: 11201]x-wiley/crsRef/2704914
9. Barrowclough C. A pilot study to assess the impact of motivational intervention on schizophrenia patients with associated substance misuse. National Research Register 2004; Vol. 3:1-4. [CSzG: 12949]x-wiley/crsRef/2704921
10. Barrowclough C. A randomized controlled trial of integrated motivational interviewing and cognitive behavior therapy (mi-cbt) for people with a schizophrenia diagnosis and substance misuse - the MIDAS trial. Schizophrenia Bulletin 2011;37 Suppl 1:295. [CSzG: 22830]x-wiley/crsRef/2704922
11. Barrowclough C. An evaluation of motivational (MI) plus cognitive therapy (CBT) for schizophrenia and substance misuse. http://www.controlled-trials.com 2003. [CSzG: 14484]x-wiley/crsRef/2704923
12. Barrowclough C. An evaluation of motivational interventions (MI) plus cognitive behaviour therapy (CBT) for schizophrenia and substance misuse - MIDAS. National Research Register 2004; Vol. 1. [CSzG: 12947]x-wiley/crsRef/12260481
13. Barrowclough C, Eisner E, Bucci S, Emsley R, Wykes T. The impact of alcohol on clinical outcomes in established psychosis: a longitudinal study. Addiction 2014;109(8):1297-305. x-wiley/crsRef/12260479
14. Barrowclough C, Emsley R, Eisner E, Beardmore R, Wykes T. Does change in cannabis use in established psychosis affect clinical outcome?. Schizophrenia Bulletin 2013;39(2):339-48. x-wiley/crsRef/12260480
15. Barrowclough C, Haddock G, Beardmore R, Conrod P, Craig T, Davies L, et al. Evaluating integrated MI and CBT for people with psychosis and substance misuse: recruitment, retention and sample characteristics of the MIDAS trial. Addictive Behaviors 2009;34(10):859-66. [CSzG: 18777]x-wiley/crsRef/2704917
16. Barrowclough C, Haddock G, Fitzsimmons M, Johnson R. Treatment development for psychosis and co-occurring substance misuse: a descriptive review. Journal of Mental Health 2006;15(6):619-32. [CSzG: 16834]x-wiley/crsRef/2704918
17. Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P, Craig T, et al. Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ 2010;341(7784):6325. [CSzG: 21934; MEDLINE: 21106618]x-wiley/crsRef/2704919
18. Barrowclough C, Meier P, Beardmore R, Emsley R. Predicting therapeutic alliance in clients with psychosis and substance misuse. Journal of Nervous and Mental Disease 2010;198(5):373-7. [CSzG: 20696]x-wiley/crsRef/2704920
19. Berry K, Gregg L, Hartwell R, Haddock G, Fitzsimmons M, Barrowclough C. Therapist-client relationships in a psychological therapy trial for psychosis and substance misuse. Drug and Alcohol Dependence 2015;152:170-6. [CSzG: 29829]x-wiley/crsRef/12260482
20. Haddock G, Beardmore R, Earnshaw P, Fitzsimmons M, Nothard S, Butler R, et al. Assessing fidelity to integrated motivational interviewing and CBT therapy for psychosis and substance use: the MI-CBT fidelity scale (MI-CTS). Journal of Mental Health 2012;21(1):38-48 2012;21(1):38-48. x-wiley/crsRef/2704925
21. Hartley S, Haddock G, Barrowclough C. Anxiety and depression and their links with delusions and hallucinations in people with a dual diagnosis of psychosis and substance misuse: A study using data from a randomised controlled trial. Behaviour Research and Therapy 2012;50(1):65-71. [CSzG: 23617]x-wiley/crsRef/2704926
22. Johnson R. MIDAS - mental health clinical trials - information for service users and carers. http://www.controlled-trials.com/ 2005. [CSzG: 12916]x-wiley/crsRef/2704927
23. Shabaruddin FH, Davies LM. Cost of delivering psychiatric inpatient care to mental health patients with psychosis and co-occuring substance use: A UK based study. Value in Health 2011;14:A291. [CSzG: 23430]x-wiley/crsRef/2704928
24. Barrowclough C, Lobbanl F, Warburton J, Choudhry I, Gregg L, Wood H, et al. Helper recap: Rethinking choices after psychosis - a phase specific psychological therapy for people with problematic cannabis use following a first episode of psychosis. Early Intervention in Psychiatry 2010;4 Suppl 1:161. [CSzG: 23469]x-wiley/crsRef/12260484
25. Barrowclough C, Marshall M, Gregg L, Fitzsimmons M, Tomenson B, Warburton J, et al. A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial. Psychological Medicine 2014;44(13):2749-61. [CSzG: 29048]x-wiley/crsRef/12260485
26. Berry K, Gregg L, Lobban F, Barrowclough C. Therapeutic alliance in psychological therapy for people with recent onset psychosis who use cannabis. Comprehensive Psychiatry 2016;67:73-80. [CSzG: 33604]x-wiley/crsRef/12260486
27. Berry K, Palmer T, Gregg L, Barrowclough C, Lobban F. Attachment and therapeutic alliance in psychological therapy for people with recent onset psychosis who use cannabis. Clinical Psychology & Psychotherapy 2018;25(3):440-5. [CSzG: 37966]x-wiley/crsRef/12260487
28. Worrell L. Helper programme (substance misuse)- a phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis (recap). http://public.ukcrn.org.uk 2011. [CSzG: 23027]x-wiley/crsRef/12260488
29. Bechdolf A, Pohlmann B, Guttgemanns J, Geyer C, Lindner K, Ferber C, et al. State-dependent motivational interviewing for people with schizophrenia and substance use: Results of a randomised controlled trial [Motivationsbehandlung für patienten mit der doppeldiagnose psychose und sucht]. Nervenarzt 2011;83(7):888-96. [MEDLINE: 21720841]x-wiley/crsRef/2704930
30. Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental iIlness. Archives of General Psychiatry 2006;63(4):426-32. [CSzG: 12628]x-wiley/crsRef/2704932
31. Bennett M, Bellack A, Dixon L, Brown C. The effects of a group based behavioral approach to substance misuse and schizophrenia. Schizophrenia Bulletin 2011;1:296. [CSzG: 22833]x-wiley/crsRef/12260489
32. Brown CH, Bennett ME, Li L, Bellack AS. Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders. Addictive Behaviors 2011;36(5):439-47. [CSzG: 22844]x-wiley/crsRef/2704933
33. NCT00295139. Behavioral treatment of drug abuse in SPMI patients. http://www.clinicaltrials.gov 2006. [CSzG: 14598]x-wiley/crsRef/12260490
34. Bogenschutz MP, Rice SL, Tonigan JS, Vogel HS, Nowinski J, Hume D, et al. 12-step facilitation for the dually diagnosed: a randomized clinical trial. Journal of Substance Abuse Treatment 2014;46(4):403-11. [CSzG: 29165; NCT00583440]x-wiley/crsRef/12260492
35. Bond GR, McDonel EC, Miller LD, Pensec M. Assertive community treatment and reference groups: an evaluation of their effectiveness for young adults with serious mental illness and substance abuse problems. Psychosocial Rehabilitation Journal 1991;15(2):31-43. [CSzG: 16926]x-wiley/crsRef/2704935
36. Bond GR, McDonel EC, Miller LD, Pensec M. Assertive community treatment and reference groups: an evaluation of their effectiveness for young adults with serious mental illness and substance abuse problems. Psychosocial Rehabilitation Journal 1991;15(2):31-43. [CSzG: 16926]x-wiley/crsRef/2704937
37. Bonsack C. Motivational intervention to reduce cannabis use in young people with psychosis: A randomized controlled trial. Early Intervention in Psychiatry 2010;4 Suppl 1:159. [CSzG: 23471]x-wiley/crsRef/2704940
38. Bonsack C, Manetti SG, Favrod J, Montagrin Y, Besson J, Bovet P, et al. Motivational intervention to reduce cannabis use in young people with psychosis: A randomized controlled trial. Psychotherapy and Psychosomatics 2011;80(5):287-97. [CSzG: 23093]x-wiley/crsRef/2704939
39. Burnam MA, Morton SC, McGlynn EA, Peterson LP, Stecher BM, Hayes C, et al. An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. Journal of Addictive Diseases 1995;14(4):111-34. [CSzG: 8751]x-wiley/crsRef/2704942
40. McGlynn EA, Boynton J, Morton SC, Stecher BM, Hayes C, Vaccaro JV, et al. Treatment for the dually diagnosed homeless: program models and implementation experience: Los Angeles. Alcohol Treatment Quarterly 1993;10(3-4):171-86. [CSzG: 4118]x-wiley/crsRef/2704943
41. Chandler D, Spicer G. Integrated treatment for jail recidivists with co-occurring psychiatric and substance use disorders. Community Mental Health Journal 2006;42(4):405-25. [CSzG: 16816]x-wiley/crsRef/2704945
42. Drake RE, Morrissey JP, Mueser KT. The challenge of treating forensic dual diagnosis clients: comment on "Integrated treatment for jail recidivists with co-occurring psychiatric and substance use disorders". Community Mental Health Journal 2006;42(4):427-32. [CSzG: 16818]x-wiley/crsRef/2704946
43. Clark RE, Teague GB, Ricketts SK, Bush PW, Xie H, McGuire TG, et al. Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders. Health Services Research 1998;33(5):1285-8. [CSzG: 5636]x-wiley/crsRef/12260493
44. Clarke RE. Family support and substance use outcomes for persons with mental illness and substance use. Schizophrenia Bulletin 2001;27(1):93-101. [CSzG: 5884]x-wiley/crsRef/12260494
45. Drake RE. Ten year follow up of dual diagnosis treatment. CRISP database accessed 10/05/02 2002. x-wiley/crsRef/12260495
46. Drake RE, McHugo GJ, Clark RE, Teague GB, Xie H, Miles K. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. American Journal of Orthopsychiatry 1998;68(2):201-15. [CSzG: 4974]x-wiley/crsRef/2704949
47. McHugo GJ, Drake RE, Teague GB, Xie H. Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatric Services 1999;50(6):818-24. [CSzG: 5155]x-wiley/crsRef/12260496
48. Xie H, Drake R, McHugo G. Are there distinctive trajectory groups in substance abuse remission over 10 years? An application of the group-based modeling approach. Administration and Policy in Mental health and Mental Health Services 2006;33(4):423-32. [CSzG: 17219]x-wiley/crsRef/12260497
49. Xie H, McHugo GJ, Fox MB, Drake RE. Substance abuse relapse in a ten-year prospective follow-up of clients with mental health and substance use disorders. Psychiatric Services 2005;56(10):1282-7. [CSzG: 16831]x-wiley/crsRef/12260498
50. Eack SM, Hogarty SS, Bangalore SS, Keshavan MS, Cornelius JR. Patterns of substance use during Cognitive Enhancement Therapy: an 18-month randomized feasibility study. Journal of Dual Diagnosis 2016;12:74-82. [CSzG: 33634]x-wiley/crsRef/12260500
51. Eack SM, Hogarty SS, Greenwald DP, Litschge MY, McKnight SA, Bangalore SS, et al. Cognitive Enhancement Therapy in substance misusing schizophrenia: Results of an 18-month feasibility trial. Schizophrenia Research 2015;161(2-3):478-83. [CSzG: 29308]x-wiley/crsRef/12260501
52. Eack SM, Hogarty SS, Greenwald DP, Litschge MY, McKnight SA, Bangalore SS, et al. Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial. Schizophrenia Bulletin 2015;41:S310. [CSzG: 29436]x-wiley/crsRef/12260502
53. Wojtalik JA, Eack SM. Fronto-limbic neuroplasticity effects of Cognitive Enhancement Therapy during emotion regulation in schizophrenia patients who abuse cannabis. Schizophrenia Bulletin 2015;41:S243. [CSzG: 29719]x-wiley/crsRef/12260503
54. Wojtalik JA, Hogarty SS, Cornelius JR, Phillips ML, Keshavan MS, Newhill CE, et al. Cognitive Enhancement Therapy improves frontolimbic regulation of emotion in alcohol and/or cannabis misusing schizophrenia: a preliminary study. Frontiers in Psychiatry 2016;6:186. [CSzG: 33452]x-wiley/crsRef/12260504
55. Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, et al. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatrica Scandinavica 2006;114(2):109-17. [CSzG: 13211]x-wiley/crsRef/2704952
56. Essock SM, Mueser KT, Drake RE, Covell NH, McHugo GJ, Frisman LK, et al. Comparison of ACT and and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatric Services 2006;57(2):185-96. [CSzG: 12680]x-wiley/crsRef/2704954
57. Kanter J. Clinical case management, case management and ACT. Psychiatric Services 2006; Vol. 57, issue 4:578. x-wiley/crsRef/2704955
58. Manuel JI. A longitudinal analysis of psychiatric medication adherence and provider continuity among individuals with co-occurring disorders. Dissertation Abstracts International Section A: Humanities and Social Sciences 2009;69(10A):4126. x-wiley/crsRef/2704957
59. Manuel JI, Covell NH, Jackson CT, Essock SM. Does assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders?. Journal of the American Psychiatric Nurses Association 2011;17(1):51-6. [CSzG: 22855]x-wiley/crsRef/2704956
60. Godley SH, Hoewing-Roberson R, Godley MD. Final MISA Report. Bloomington, IN: Lighthouse Institute, 1994. [CSzG: 970]x-wiley/crsRef/2704959
61. Gouzoulis-Mayfrank E, Konig S, Koebke S, Schness T, Schmitz-Buhl M, Daumann J. Trans-sector integrated treatment in psychosis and addiction. Deutsches Arzteblatt International 2015;112(41):683-91. [CSzG: 33168]x-wiley/crsRef/12260506
62. U1111-1119-5851. Evaluation of an integrative therapy approach for the comorbidity of psychosis and addiction. http://www.drks.de/DRKS00000671 2011. [CSzG: 22748]x-wiley/crsRef/12260507
63. Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Mental Health Journal 2003;39(3):189-202. [CSzG: 9901]x-wiley/crsRef/2704961
64. Graham HL, Birchwood M, Griffith E, Freemantle N, McCrone P, Stefanidou CA, et al. A pilot study to assess the feasibility and impact of a brief motivational intervention on problem drug and alcohol use in adult mental health inpatient units: study protocol for a randomized controlled trial. Trials 2014;15(1):308. [CSzG: 29050]x-wiley/crsRef/12260509
65. Graham HL, Copello A, Griffith E, Freemantle N, McCrone P, Clarke L, et al. Pilot randomised trial of a brief intervention for comorbid substance misuse in psychiatric in-patient settings. Acta Psychiatrica Scandinavica 2016;133(4):298-309. [CSzG: 33324]x-wiley/crsRef/12260510
66. ISRCTN43548483. A pilot study to assess the feasibility and impact of a motivational intervention (MI) on problem drug and alcohol use in adult mental health inpatient units. http://isrctn.org/ISRCTN43548483 2014. [CSzG: 28909]x-wiley/crsRef/12260511
67. Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patients. American Journal on Addictions 1995;4(1):33-42. [CSzG: 5029]x-wiley/crsRef/2704963
68. Hellerstein DJ, Rosenthal RN, Miner CR. Integrating services for schizophrenia and substance abuse. Psychiatric Quarterly 2001;72(4):291-306. [CSzG: 8206]x-wiley/crsRef/2704964
69. Hickman ME. The effects of personal feedback on alcohol intake in dually diagnosed clients: an empirical study of William R. Miller's motivational enhancement therapy. Unpublished thesis. University Graduate School, Dept. Counseling Psychology, Indiana University 1997. [CSzG: 4153]x-wiley/crsRef/2704966
70. Fohlmann AH, Hjorthoej C, Larsen A, Nordentoft M. CapOpus. randomized clinical trial: Specialized addiction treatment (MI & CBT) versus treatment as usual for young patients with cannabis abuse and psychosis. Early Intervention in Psychiatry 2010;4 Suppl 1:159. [CSzG: 23478]x-wiley/crsRef/2704968
71. Fohlmann AH, Hjorthoej C, Larsen A, Nordentoft M. CapOpus. randomized clinical trial: Specialized addiction treatment (MI & CBT) versus treatment as usual for young patients with cannabis abuse and psychosis. Early Intervention in Psychiatry 2010;4 Suppl 1:160. [CSzG: 23478]x-wiley/crsRef/2704969
72. Hjorthaj CR. Validity of self-reported cannabis use as measured by the timeline follow-back instrument in a trial randomizing people with comorbid cannabis use disorder and schizophrenia spectrum disorder. Early Intervention in Psychiatry 2010;4 Suppl 1:160. [CSzG: 23483]x-wiley/crsRef/2704971
73. Hjorthoj C, Fohlmann A, Larsen AM, Madsen MT, Vesterager L, Gluud C, et al. Design paper: the CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. Trials 2008;9:42. [CSzG: 16594]x-wiley/crsRef/2704972
74. Hjorthoj CR, Fohlmann A, Larsen A-M, Madsen MTR, Vesterager L, Gluud C, et al. Interim analysis of the CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. Schizophrenia Research 2010;117(2-3):190. [CSzG: 20563]x-wiley/crsRef/2704973
75. Hjorthoj CR, Fohlmann A, Larsen AM, Arendt M, Nordentoft M. Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial. Addiction 2011;107(6):1123-31. [CSzG: 23547; MEDLINE: 22151583]x-wiley/crsRef/12260512
76. Hjorthoj CR, Orlovska S, Fohlmann A, Nordentoft M. Psychiatric treatment following participation in the CapOpus randomized trial for patients with comorbid cannabis use disorder and psychosis. Schizophrenia Research 2013;151(1-3):191-6. [CSzG: 28381]x-wiley/crsRef/12260513
77. Hjorthoj CR, Vesterager L, Nordentoft M. Test-retest reliability of the Danish adult reading test in patients with comorbid psychosis and cannabis-use disorder. Nordic Journal of Psychiatry 2013;67(3):159-63. [CSzG: 28766; MEDLINE: 22624828]x-wiley/crsRef/2704975
78. Hjorthøj CR, Fohlmann A, Larsen AM, Gluud C, Arendt M, Nordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychological Medicine 2013;43(7):1499-510. [CSzG: 28754; PUBMED: 23040144]x-wiley/crsRef/2704970
79. NCT00484302. Cannabis and psychosis randomized clinical trial: specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. http://www.clinicaltrials.gov 2007. [CSzG: 15056]x-wiley/crsRef/2704976
80. Nordentoft M, Hjorthoj C, Fohlmann A. Capopus trial: An observer-blinded RCT of specialized addiction treatment versus standard treatment for young patients with cannabis. Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal 2009;24:S1178. [CSzG: 20894]x-wiley/crsRef/12260514
81. Toftdahl NG, Nordentoft M, Hjorthoj C. The effect of changes in cannabis exposure on psychotic symptoms in patients with comorbid cannabis use disorder. Journal of Dual Diagnosis 2016;12(2):129-36. [CSzG: 33821]x-wiley/crsRef/12260515
82. Jerrell JM. Cost-effective treatment for persons with dual disorders. New Directions for Mental Health Services 1996;70(Summer):79-91. [CSzG: 16821]x-wiley/crsRef/2704982
83. Jerrell JM, Hu TW, Ridgely MS. Cost-effectiveness of substance disorder interventions for people with severe mental illness. Journal of Mental Health Administration 1994;21(3):283-97. [CSzG: 1166]x-wiley/crsRef/2704979
84. Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. Journal of Nervous and Mental Disease 1995;183(9):566-76. [CSzG: 3727]x-wiley/crsRef/2704980
85. Jerrell JM, Ridgely MS. Impact of robustness of program implementation on outcomes of clients in dual diagnosis programs. Psychiatric Services 1999;50(1):109-12. [CSzG: 16917]x-wiley/crsRef/2704981
86. Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. Journal of Nervous and Mental Disease 1995;183(9):566-76. [CSzG: 3727]x-wiley/crsRef/2704984
87. Kavanagh DJ, Young R, White A, Saunders JB, Wallis J, Shockley N, et al. A brief motivational intervention for substance misuse in recent-onset psychosis. Drug and Alcohol Review 2004;23(2):151-5. [CSzG: 8309]x-wiley/crsRef/2704986
88. Kemp R, Harris A, Vurel E, Sitharthan T. Stop using stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems. Australasian Psychiatry 2007;15(6):490-3. [CSzG: 15549; MEDLINE: 17852064]x-wiley/crsRef/2704988
89. Lehman AF, Herron JD, Schwartz RP, Myers CP. Rehabilitation for adults with severe mental illness and substance use disorders: a clinical trial. Journal of Nervous and Mental Disease 1993;181(2):86-90. [CSzG: 1646]x-wiley/crsRef/2704990
90. Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, O'Connor JJ, et al. A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophrenia Research 2013;143(1):138-42. [CSzG: 25073]x-wiley/crsRef/2704992
91. Maloney MP. Reducing criminal recidivism in jail-incarcerated mothers with co-occurring disorders. Manuscript kindly provided by Dr Maloney - no further details given. x-wiley/crsRef/2704994
92. Angelo FN, McDonell MG, Lewin MR, Srebnik D, Lowe J, Roll J, et al. Predictors of stimulant abuse treatment outcomes in severely mentally ill outpatients. Drug and Alcohol Dependence 2013;131(1-2):162-5. x-wiley/crsRef/12260516
93. McDonell MG, Srebnik D, Angelo F, McPherson S, Lowe JM, Sugar A, et al. Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. American Journal of Psychiatry 2013;170(1):94-101. [CSzG: 24857]x-wiley/crsRef/12260517
94. Murphy SM, McDonell MG, McPherson S, Srebnik D, Angelo F, Roll JM, et al. An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness. Drug and Alcohol Dependence 2015;153:293-9. [CSzG: 29903]x-wiley/crsRef/12260518
95. NCT00809770. Contingency management of psychostimulant abuse in the severely mentally ill. ClinicalTrials.gov 2008. [CSzG: 17380]x-wiley/crsRef/2704997
96. Weiss RD. Contingency management for patients with serious mental illness and stimulant dependence. American Journal of Psychiatry 2013;170(1):6-8. x-wiley/crsRef/2704998
97. Lowe JM, McDonell MG, Leickly E, Angelo FA, Vilardaga R, McPherson S, et al. Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in addiction treatment patients. Alcoholism: Clinical and Experimental Research 2015;39(5):905-10. x-wiley/crsRef/12260520
98. McDonell MG, Leickly E, McPherson S, Skalisky J, Hirchak K, Oluwoye O, et al. Pretreatment ethyl glucuronide levels predict response to a contingency management intervention for alcohol use disorders among adults with serious mental illness. American Journal on Addictions 2017;26(7):673-5. [CSzG: 36340]x-wiley/crsRef/12260521
99. McDonell MG, Leickly E, McPherson S, Skalisky J, Srebnik D, Angelo F, et al. A randomized controlled trial of ethyl glucuronide- based contingency management for outpatients with co-occurring alcohol use disorders and serious mental Illness. American Journal of Psychiatry 2017;174(4):370-7. [CSzG: 35589]x-wiley/crsRef/12260522
100. McDonell MG, Skalisky J, Leickly E, McPherson S, Battalio S, Nepom JR, et al. Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients. Drug and Alcohol Dependence 2015;157:184-7. x-wiley/crsRef/12260523
101. NCT01567943. Contingency management of alcohol abuse in the severely mentally ill. http://ClinicalTrials.gov/show/NCT01567943 2012. [CSzG: 23792]x-wiley/crsRef/12260524
102. Oluwoye O, Leickly E, Skalisky J, McPherson S, Hirchak K, Srebnik D, et al. Serious mental illness in heavy drinkers is associated with poor treatment outcomes in outpatients with co-occurring disorders. International Journal of Mental Health Addiction 2018;16(3):672-9. [CSzG: 37902]x-wiley/crsRef/12260525
103. Skalisky J, Leickly E, Oluwoye O, McPherson SM, Srebnik D, Roll JM, et al. Prevalence and correlates of cannabis use in outpatients with serious mental illness receiving treatment for alcohol use disorders. Cannabis and Cannabinoid Research 2017;2(1):133-8. [CSzG: 36516]x-wiley/crsRef/12260526
104. Calsyn RJ, Yonker RD, Lemming MR, Morse GA, Klinkenberg WD. Impact of assertive community treatment and client characteristics on criminal justice outcomes in dual disorder homeless individuals. Criminal Behaviour and Mental Health 2005;15(4):236-48. [CSzG: 16813]x-wiley/crsRef/2705000
105. Fletcher TD, Cunningham JL, Calsyn RJ, Morse GA, Klinkenberg WD. Evaluation of treatment programs for dual disorder individuals: modeling longitudinal and mediation effects. Administration and Policy in Mental Health 2008;35(4):319-36. [CSzG: 16624; MEDLINE: 18506618]x-wiley/crsRef/2705001
106. Morse GA, Calsyn RJ, Klinkenberg WD, Cunningham J, Lemming MR. Integrated treatment for homeless clients with dual disorders: a quasi-experimental evaluation. Journal of Dual Diagnosis 2008;4(3):219-37. [CSzG: 19618]x-wiley/crsRef/2705002
107. Morse GA, Calsyn RJ, Klinkenberg WD, Helminiak TW, Wolff N, Drake RE, et al. Treating homeless clients with severe mental illness and substance use disorders: costs and outcomes. Community Mental Health Journal 2006;42(4):377-404. [CSzG: 13863]x-wiley/crsRef/2705003
108. Naeem F, Kingdon D, Turkington D. Cognitive behaviour therapy for schizophrenia in patients with mild to moderate substance misuse problems. Cognitive Behaviour Therapy 2005;34(4):207-15. [CSzG: 12597]x-wiley/crsRef/2705005
109. Turkington D, Kingdon D, Turner T. Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. British Journal of Psychiatry 2002;180:523-7. [CSzG: 8740]x-wiley/crsRef/2705006
110. Nagel T, Robinson G, Condon J, Trauer T. Approach to treatment of mental illness and substance dependence in remote indigenous communities: results of a mixed methods study. Australian Journal of Rural Health 2009;17(4):174-82. [CSzG: 18782; MEDLINE: 19664081]x-wiley/crsRef/2705008
111. O'Connell MJ, Flanagan EH, Delphin-Rittmon ME, Davidson L. Enhancing outcomes for persons with co-occurring disorders through skills training and peer recovery support. Journal of Mental Health 2018;in press:(online 10 March 2017). [CSzG: 35896; DOI: 10.1080/09638237.2017.1294733]x-wiley/crsRef/12260528
112. NCT01478815. Contingency management for persons with severe mental illness. http://ClinicalTrials.gov/show/NCT01478815 2011. [CSzG: 23332]x-wiley/crsRef/12260530
113. Petry NM, Alessi SM, Rash Carla J. A randomized study of contingency management in cocaine-dependent patients with severe and persistent mental health disorders. Drug and Alcohol Dependence 2013;130:234-7. [CSzG: 28275]x-wiley/crsRef/12260531
114. Rosenblum A, Matusow H, Fong C, Vogel H, Uttaro T, Moore TL, et al. Efficacy of dual focus mutual aid for persons with mental illness and substance misuse. Drug and Alcohol Dependence 2014;135:78-87. [CSzG: 27823]x-wiley/crsRef/12260533
115. Pantalon MV, Swanson AJ. Use of the University of Rhode Island Change Assessment to measure motivational readiness to change in psychiatric and dually diagnosed individuals. Psychology of Addictive Behaviors 2003;17(2):91-7. [CSzG: 9830]x-wiley/crsRef/12260534
116. Swanson AJ, Pantalon MV, Cohen KR. Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. Journal of Nervous and Mental Disease 1999;187(10):630-5. [CSzG: 9248]x-wiley/crsRef/2705010
117. Tracy K, Babuscio T, Nich C, Kiluk B, Carroll KM, Petry NM, et al. Contingency management to reduce substance use in individuals who are homeless with co-occurring psychiatric disorders. American Journal of Drug and Alcohol Abuse 2007;33(2):253-8. [CSzG: 14807; MEDLINE: 17497548]x-wiley/crsRef/2705012
118. Audier C, Mulder CL, Staring A, Van Der Hoorn BE, Hakkaart-vanRoijen L, Blanken P. Money for medication: A randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with a psychotic disorder and co-morbid substance abuse. Schizophrenia Bulletin 2011;1:294-5. x-wiley/crsRef/2705014
119. Bachmann KM, Moggi F, Hirsbrunner HP, Donati R, Brodbeck J, Hirsbrunner H. An integrated treatment program for dually diagnosed patients. Psychiatric Services 1997;48(3):314-6. x-wiley/crsRef/12260536
120. Bagoien G, Bjorngaard J, Ostensen C, Romundstad P, Morken G. Motivational interviewing to patients with comorbid substance use admitted to an acute psychiatric department. Psychiatrische Praxis 2011;38:S10. x-wiley/crsRef/2705018
121. Bagoien G, Bjorngaard JH, Ostensen C, Reitan SK, Romundstad P, Morken G. The effects of motivational interviewing on patients with comorbid substance use admitted to a psychiatric emergency unit - a randomised controlled trial with two year follow-up. BMC Psychiatry 2013;13:93. [PUBMED: 23517244]x-wiley/crsRef/2705019
122. Barkhof E, Meijer CJ, De Sonneville LM, Linszen DH, de Haan L. The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. Schizophrenia Bulletin 2013;39(6):1242-51. x-wiley/crsRef/12260538
123. Barrowclough C, Haddock G, Lobban F, Jones S, Siddle R, Roberts C, et al. Group cognitive-behavioural therapy for schizophrenia. British Journal of Psychiatry 2006;189:527-32. x-wiley/crsRef/2705021
124. Battersby MW, Beattie J, Pols RG, Smith DP, Condon J, Blunden S. A randomised controlled trial of the Flinders Program of chronic condition management in Vietnam veterans with co-morbid alcohol misuse, and psychiatric and medical conditions. Australian and New Zealand Journal of Psychiatry 2013;47(5):451-62. x-wiley/crsRef/12260540
125. Bechdolf A, Knost B, Kuntermann C, Schiller S, Klosterkotter J, Hambrecht M, et al. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. Acta Psychiatrica Scandinavica 2004;110(1):21-8. x-wiley/crsRef/2705023
126. Beebe LH, Smith K, Burk R, McIntyre K, Dessieux O, Tavakoli A, et al. Motivational intervention increases exercise in schizophrenia and co-occurring substance use disorders. Schizophrenia Research 2012;135(1-3):204-5. x-wiley/crsRef/2705025
127. Bell MD. Cognitive remediation with work therapy in the initial phase of substance abuse treatment. Schizophrenia Bulletin 2011;Suppl 1:296. x-wiley/crsRef/2705027
128. Bennett ME, Bellack AS, Gearon JS. Treating substance abuse in schizophrenia. An initial report. Journal of Substance Abuse Treatment 2001;20:163-75. x-wiley/crsRef/2705029
129. Bowen RC, D'Arcy C, Keegan D, Senthilselvan A. A controlled trial of cognitive behavioural treatment of panic in alcoholic inpatients with comorbid panic disorder. Addictive Behaviours 2000;25(4):593-7. x-wiley/crsRef/2705035
130. Brooner RK, Kidorf MS, King VL, Peirce J, Neufeld K, Stoller K, et al. Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation. Addiction (Abingdon, England) 2013;108(11):1942-51. x-wiley/crsRef/12260542
131. Brown RA, Abrantes AM, Minami H, Prince MA, Bloom EL, Apodaca TR, et al. Motivational interviewing to reduce substance use in adolescents with psychiatric comorbidity. Journal of Substance Abuse Treatment 2015;59:20-9. x-wiley/crsRef/12260544
132. Carey KB, Purnine DM, Maisto SA, Carey MP. Enhancing readiness-to-change substance abuse in persons with schizophrenia. A four-session motivation-based intervention. Behaviour Modification 2001;25(3):331-84. x-wiley/crsRef/2705039
133. Carey MP, Carey KB, Maisto SA, Gordon CM, Schroder KE, Vanable PA. Reducing HIV-risk behavior among adults receiving outpatient psychiatric treatment: Results from a randomized controlled trial. Journal of Consulting and Clinical Psychology 2004;72(2):252-68. x-wiley/crsRef/2705040
134. ACTRN12610000249055. A randomised control trial of a group based intervention and relapse prevention package for substance misuse and psychosis. Australian New Zealand Clinical Trials Registry 2010. x-wiley/crsRef/12260546
135. Castle DJ, James W, Koh G, Kisely N, Preston N. An RCT A group-based intervention for substance abuse in schizophrenia. Schizophrenia Research 2003;60:276-7. x-wiley/crsRef/12260547
136. Castle DJ, James W, Koh G, Wightman P, Kisely S, Spencer C, et al. Substance use in schizophrenia: why do people use, and what can be done about it?. Schizophrenia Research 2002;53(3 Suppl 1):178. x-wiley/crsRef/12260548
137. Clarke GN, Herinckz HA, Kinney RF, Paulson RI, Cutler DL, Lewis K, et al. Psychiatric hospitalizations, arrests, emergency room visits, and homelessness of clients with serious and persistent mental illness: Findings from a randomized trial of two ACT programs vs. usual care. Mental Health Services Research 2000;2(3):155-64. x-wiley/crsRef/2705052
138. Clausen H, Ruud T, Odden S, Saltyte Benth J, Heiervang KS, Stuen HK, et al. Hospitalisation of severely mentally ill patients with and without problematic substance use before and during Assertive Community Treatment: an observational cohort study. BMC Psychiatry 2016;16:125. x-wiley/crsRef/12260550
139. DeMarce JM, Lash SJ, Stephens RS, Grambow SC, Burden JL. Promoting continuing care adherence among substance abusers with co-occurring psychiatric disorders following residential treatment. Addictive Behaviors 2008;33(9):1104-12. [MEDLINE: 18573617]x-wiley/crsRef/2705066
140. de Waal MM, Kikkert MJ, Blankers M, Dekker JJ, Goudriaan AE. Self-wise, Other-wise, Streetwise (SOS) training: a novel intervention to reduce victimization in dual diagnosis psychiatric patients with substance use disorders: protocol for a randomized controlled trial. BMC Psychiatry 2015;15:267. [NTR 4472]x-wiley/crsRef/12260552
141. Drake RE, Xie X, McHugo GJ, Shumway M. Three-year outcomes of long-term patients with co-occurring bipolar and substance use disorders. Biological Psychiatry 2004;56(November 15):749-56. x-wiley/crsRef/2705068
142. Drake RE, McHugo GJ, Xie H, Fox M, Packard J, Helmsetter B. Ten-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin. 2006;32(3):464-73. x-wiley/crsRef/2705070
143. Drebing CE, Van Ormer EA, Krebs C, Rosenheck R, Rounsaville B, Herz L, et al. The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. Journal of Applied Behavior Analysis 2005;38(3):359-72. x-wiley/crsRef/2705072
144. Drebing CE, Van Ormer EA, Mueller L, Hebert M, Penk WE, Petry NM, et al. Adding contingency management intervention to vocational rehabilitation: outcomes for dually diagnosed veterans. Journal of Rehabilitation Research and Development 2007;44(6):851-65. [MEDLINE: 18075942]x-wiley/crsRef/2705074
145. Eberhard S, Nordstrom G, Hoglund P, Ojehagen A. Secondary prevention of hazardous alcohol consumption in psychiatric out-patients: a randomised controlled study. Social Psychiatry and Psychiatric Epidemiology 2009;12:1013-21. x-wiley/crsRef/2705076
146. Faber G, Smid HG, Van Gool AR, Wunderink L, Van Den Bosch RJ, Wiersma D. Continued cannabis use and outcome in first-episode psychosis: Data from a randomized, open-label, controlled trial. Journal of Clinical Psychiatry 2012;73(5):632-8. x-wiley/crsRef/2705080
147. Fiszdon JM, Kurtz MM, Choi J, Bell MD, Martino S. Motivational interviewing to increase cognitive rehabilitation adherence in schizophrenia. Schizophrenia Bulletin 2016;42(2):327-34. x-wiley/crsRef/12260554
148. Gaughran F, Stahl D, Ismail K, Atakan Z, Lally J, Gardner-Sood P, et al. Improving physical health and reducing substance use in psychosis--randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial. BMC Psychiatry 2013;13:263. x-wiley/crsRef/12260556
149. Gaughran F, Stahl D, Ismail K, Greenwood K, Atakan Z, Gardner-Sood P, et al. Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPaCT). BMC Psychiatry 2017;17(1):413. x-wiley/crsRef/12260557
150. Smith S, Greenwood K, Atakan Z, Sood P, Ohlsen R, Papanastasiou E, et al. The impact study - motivating a change in health behaviour. European Psychiatry. 2011; Vol. 26, issue (Suppl 1):2151. x-wiley/crsRef/12260558
151. Alvarez-Jimenez M, Gleeson J, Cotton S, Wade D, Gee D, Pearce T, et al. Duration of untreated psychosis, insight and adherence with cognitive-behavioural therapy in first-episode psychosis. Early Intervention in Psychiatry 2008;2(Suppl 1):A101. x-wiley/crsRef/12260560
152. Cotton SM, Gleeson JF, Alvarez-Jimenez M, McGorry PD. Quality of life in patients who have remitted from their first episode of psychosis. Schizophrenia Research 2010;121(1-3):259-65. x-wiley/crsRef/12260561
153. Gleeson J, Alvarez-Jimenez M, Killackey E, McGorry P. Two year outcomes from the episode ii trial. Early Intervention in Psychiatry 2010;4(Suppl 1):24. x-wiley/crsRef/12260562
154. Gleeson J, Cotton S, Alvarez-Jimenez M, Wade D, Gee D, Crisp K, et al. An RCT of relapse prevention therapy for first-episode psychosis patients. Early Intervention in Psychiatry 2008;2(Suppl 1):A20. x-wiley/crsRef/12260563
155. Gleeson J, Wade D, Castle D, Gee D, Crisp K, Pearce T, et al. The EPISODE II trial of cognitive and family therapy for relapse prevention in early psychosis: rationale and sample characteristics. Journal of Mental Health 2008;17(1):19-32. x-wiley/crsRef/12260564
156. Gleeson J, Wade D, Mcgorry P, Albiston D, Castle D, Gilbert M, et al. Episode II: prevention of relapse following early psychosis. Schizophrenia Research 2004;70(1):61-2. x-wiley/crsRef/12260565
157. Gleeson JF, Cotton SM, Alvarez-Jimenez M, Wade D, Crisp K, Newman B, et al. Family outcomes from a randomized control trial of relapse prevention therapy in first-episode psychosis. Journal of Clinical Psychiatry 2010;71(4):475-83. x-wiley/crsRef/12260566
158. Gleeson JF, Cotton SM, Alvarez-Jimenez M, Wade D, Gee D, Crisp K, et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. Journal of Clinical Psychiatry 2009;70(4):477-86. [ACTRN126050005144606]x-wiley/crsRef/12260567
159. Gonzalez-Blanch C, Gleeson JF, Koval P, Cotton SM, McGorry PD, Alvarez-Jimenez M. Social functioning trajectories of young first-episode psychosis patients with and without cannabis misuse: a 30-month follow-up study. PLOS One 2015;10(4):e0122404. x-wiley/crsRef/12260568
160. Newman B. EPISODE II: Prevention of relapse following early psychosis. Australian New Zealand Clinical Trials Registry 2003. x-wiley/crsRef/12260569
161. Goldstein G, Haas GL, Shemansky WJ, Barnett B, Salmon-Cox S. Rehabilitation during alcohol detoxication in comorbid neuropsychiatric patients. Journal of Rehabilitation Research and Development 2005;42(2):225-34. [MEDLINE: 15944887]x-wiley/crsRef/2705091
162. Harrison J, Curtis A, Cousins L, Spybrook J. Integrated dual disorder treatment implementation in a large state sample. Community Mental Health Journal 2017;53(3):358-66. x-wiley/crsRef/12260571
163. Havassy BE, Shropshire MS, Quigley LA. Effects of substance dependence on outcomes of patients in a randomized trial of two case management models. Psychiatric Services 2000;51(5):639-44. x-wiley/crsRef/2705095
164. Herman SE, BootsMiller B, Jordan L, Mowbray CT, Brown G, Deiz N, et al. Immediate outcomes of substance abuse treatment within a state psychiatric hospital. Journal of Mental Health Administration 1997;24(2):126-38. x-wiley/crsRef/2705101
165. Herman SE, Frank KA, Mowbray CT, Ribisl K, Davidson WS, BootsMiller B, et al. Longitudinal effects of integrated treatment on alcohol use for persons with serious mental illness and substance use disorders. Journal of Behavioral Health Services and Research 2000;27(3):286-302. x-wiley/crsRef/2705102
166. Hulse GK, Tait RJ. Six-month outcomes associated with a brief alcohol intervention for adult in-patients with psychiatric disorders. Drug and Alcohol Review 2002;21(2):105-12. x-wiley/crsRef/2705104
167. ISRCTN58667926. Impact - improving physical health and reducing substance use in severe mental illness: randomised controlled trial of a health promotion intervention. http://public.ukcrn.org.uk/ 2011. x-wiley/crsRef/2705108
168. James W, Preston NJ, Koh G, Spencer C, Kisely SR, Castle DJ. A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychological Medicine 2004;34(6):983-90. x-wiley/crsRef/2705110
169. Jerrell JM, Wilson JL, Hiller DC. Issues and outcomes in integrated treatment programs for dual disorders. Journal of Behavioral Health Services & Research 2000;27(3):303-13. x-wiley/crsRef/2705112
170. Kelly JF, McKellar JD, Moos R. Major depression in patients with substance use disorders: relationship to 12-step self-help involvement and substance use outcomes. Addiction 2003;98(4):499-508. x-wiley/crsRef/2705122
171. Kidorf M, Brooner RK, Gandotra N, Antoine D, King V L, Peirce J, et al. Reinforcing integrated psychiatric service attendance in an opioid-agonist program: A randomized and controlled trial. Drug and Alcohol Dependence 2013;133(1):30-6. x-wiley/crsRef/12260573
172. Kidorf M, King VL, Peirce J, Gandotra N, Ghazarian S, Brooner RK. Substance use and response to psychiatric treatment in methadone-treated outpatients with comorbid psychiatric disorder. Journal of Substance Abuse Treatment 2015;51:64-9. x-wiley/crsRef/12260574
173. Allott KA, Chinnery GL, Cotton SM, Jackson HJ, Killackey EJ. Does individual placement and support compensate for neurocognitive deficit in first-episode psychosis?. Early Intervention in Psychiatry 2012;6:14. x-wiley/crsRef/12260576
174. Arnold C, Allott K, Farhall J, Killackey E, Cotton S. Neurocognitive and social cognitive predictors of cannabis use in first-episode psychosis. Schizophrenia Research 2015;168(1-2):231-7. x-wiley/crsRef/12260577
175. Caruana E, Cotton S, Killackey E, Allott K. The relationship between cognition, job complexity, and employment duration in first-episode psychosis. Psychiatric Rehabilitation Journal 2015;38(3):210-7. x-wiley/crsRef/12260578
176. Cotton S, Allott K, Chinnery G, Jackson H, Killackey E. The relationship between vocational functioning and quality of life in patients with first episode psychosis. Early Intervention in Psychiatry 2014;8:81. x-wiley/crsRef/12260579
177. Herniman SE, Allott KA, Killackey E, Hester R, Cotton SM. The effect of comorbid depression on facial and prosody emotion recognition in first-episode schizophrenia spectrum. Journal of Affective Disorders 2017;208:223-9. x-wiley/crsRef/12260580
178. Karambelas GJ, Cotton SM, Farhall J, Killackey E, Allott KA. Contribution of neurocognition to 18-month employment outcomes in first-episode psychosis. Early Intervention in Psychiatry 2019;13(3):453-60. [DOI: 10.1111/eip.12504]x-wiley/crsRef/12260581
179. Killackey E, Allott K, Cotton S, Chinnery G, Jackson H. Baseline to 18 months: Main results from a randomized controlled trial of individual placement and support for young people with first-episode psychosis. Early Intervention in Psychiatry 2014;8:152. x-wiley/crsRef/12260582
180. Killackey E, Allott K, Cotton SM, Chinnery G, Jackson HJ, Baksheev G. The role of neurocognition within a randomised controlled trial of Individual Placement and Support for first-episode psychosis. Schizophrenia Bulletin 2013;39:S264-5. x-wiley/crsRef/12260583
181. Killackey E, Allott K, Cotton SM, Jackson H, Scutella R, Tseng YP, et al. A randomized controlled trial of vocational intervention for young people with first-episode psychosis: method. Early Intervention in Psychiatry 2013;7(3):329-37. [ACTRN12608000094370]x-wiley/crsRef/12260584
182. Killackey E, Jackson H, Allott K, Cotton S. Vocational recovery in first episode psychosis: Preliminary results from a large randomised controlled trial of individual placement and support. Schizophrenia Research 2014;153(Suppl. 1):S282. x-wiley/crsRef/12260585
183. Killackey EJ, Allott KA, Cotton SM, Chinnery GL, Sun P, Collins Z, et al. Vocational recovery in first-episode psychosis: First results from a large randomized controlled trial of ips. Early Intervention in Psychiatry 2012;6:13. x-wiley/crsRef/12260586
184. On ZX, Cotton S, Farhall J, Killackey E, Allott K. Relationship between duration of untreated psychosis and neurocognition and social cognition in first-episode psychosis. Schizophrenia Research 2016;176(2-3):529-32. x-wiley/crsRef/12260587
185. Lozano BE, LaRowe SD, Smith JP, Tuerk P, Roitzsch J. Brief motivational feedback may enhance treatment entry in veterans with comorbid substance use and psychiatric disorders. American Journal on Addictions 2013;22(2):132-5. x-wiley/crsRef/12260589
186. Magura S, Laudet AB, Mahmood D, Rosenblum A, Vogel HS, Knight EL. Role of self-help processes in achieving abstinence among dually diagnosed persons. Addictive Behaviours 2003;28(3):399-413. x-wiley/crsRef/2705130
187. Mangrum LF, Spence RT, Lopez M. Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. Journal of Substance Abuse Treatment 2006;30(1):79-84. x-wiley/crsRef/2705132
188. Martino S, Carroll KM, O'Malley SS, Rounsaville BJ. Motivational interviewing with psychiatrically ill substance abusing patients. American Journal on Addictions 2000;9(1):88-91. x-wiley/crsRef/2705134
189. Martino S, Carroll KM, Nich C, Rounsaville BJ. A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders. Addiction 2006;101(10):1479-92. x-wiley/crsRef/2705136
190. McGurk SR, Mueser KT, Derosa TJ, Wolfe R. Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation. Schizophrenia Bulletin 2009;35(2):319-35. x-wiley/crsRef/2705140
191. Mercer McFadden C, Drake RE, Brown NB, Fox RS. The Community Support Program demonstrations of services for young adults with severe mental illness and substance use disorders, 1987-1991. Psychiatric Rehabilitation Journal 1997;20(3):13-24. x-wiley/crsRef/2705146
192. Mueser KT, Essock SM, Drake RE, Wolfe RS, Frisman L. Rural and urban differences in patients with a dual diagnosis. Schizophrenia Research 2001;48(1):93-107. x-wiley/crsRef/2705154
193. Mueser K, Glynn SM, Xie H, Zarate R, Cather C, Fox L, et al. Family psychoeducation with patients who have co-occurring substance use disorders and severe mental illness. Schizophrenia Research 2010;117(2-3):121. x-wiley/crsRef/12260590
194. Mueser KT, Glynn SM, Cather C, Xie H, Zarate R, Smith LF, et al. A randomized controlled trial of family intervention for co-occurring substance use and severe psychiatric disorders. Schizophrenia Bulletin 2013;39(3):658-72. [MEDLINE: 22282453]x-wiley/crsRef/12260591
195. Mueser KT, Glynn SM, Cather C, Zarate R, Fox L, Feldman J, et al. Family intervention for co-occurring substance use and severe psychiatric disorders: participant characteristics and correlates of initial engagement and more extended exposure in a randomized controlled trial. Addictive Behaviors 2009;34(10):867-77. [MEDLINE: 19375870]x-wiley/crsRef/2705156
196. NCT00043693. Family intervention for SMI and substance use disorder. http://www.clinicaltrials.gov 2002. x-wiley/crsRef/2705162
197. NCT00316303. Effectiveness of the screen, test, immunize, reduce risk, and refer (stirr) intervention for people with both a mental and substance abuse disorder. http://clinicaltrials.gov 2009. x-wiley/crsRef/2705164
198. NCT00447720. HIV prevention among substance abusing SMI. http://www.clinicaltrials.gov 2007. x-wiley/crsRef/2705166
199. NCT00495911. A randomized controlled trial of individual therapy for first episode psychosis. http://www.clinicaltrials.gov 2007. x-wiley/crsRef/2705168
200. NCT01361698. Illness Management and Recovery (IMR) in Danish community mental health centres. http://ClinicalTrials.gov/show/NCT01361698 2011. x-wiley/crsRef/2705172
201. NCT02264327. Phase II Motivational Interviewing: an experiential online training tool. http://ClinicalTrials.gov/show/NCT02264327 2014. x-wiley/crsRef/12260593
202. Noordraven EL, Wierdsma AI, Blanken P, Bloemendaal AF, Staring AB, Mulder CL. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial. Lancet Psychiatry 2017;4(3):199-207. [NTR2350]x-wiley/crsRef/12260595
203. Nuijten M, Blanken P, Van Der Hoorn B, Van Den Brink W, Hendriks V. A randomised controlled trial of outpatient versus inpatient integrated treatment of dual diagnosis patients: A failed but informative study. Mental Health and Substance Use 2012;5(2):132-47. x-wiley/crsRef/2705174
204. Nuttbrock L, Ng-Mak DS, Rahav M, Rivera JJ. Pre- and post-admission attrition of homeless, mentally ill chemical abusers referred to residential treatment programs. Addiction 1997;92(10):1305-16. x-wiley/crsRef/2705176
205. Nuttbrock LA, Rahav M, Rivera JJ, Ng-Mak DS, Link BG. Outcomes of homeless mentally ill chemical abusers in community residences and a therapeutic community. Psychiatric Services 1998;49(1):68-76. x-wiley/crsRef/2705177
206. Rahav M, Rivera JJ, Collins J, Ng-Mak D, Sturz EL, Struening EL, et al. Bringing experimental research designs into existing treatment programs: the case of community-based treatment of the dually diagnosed. In: Fletcher BW//Inciardi JA//Horton AM editor(s). Drug Abuse Treatment: the Implementation of Innovative Approaches. Westport, Connecticut, USA: Greenwood Press, 1994:79-93. x-wiley/crsRef/12260596
207. Rahav M, Rivera JJ, Nuttbrock L, Ng Mak D. Characteristics and treatment of homeless, mentally ill, chemical-abusing men. Journal of Psychoactive Drugs 1995;27(1):93-103. x-wiley/crsRef/2705178
208. Odom AE. A randomized study of integrated outpatient treatment and assertive community treatment for patients with comorbid mental illness and substance use disorders: comparing treatment outcome for domiciled and homeless patients [PhD thesis]. New School University, 2005. x-wiley/crsRef/2705262
209. Brooks AJ, Penn PE. Comparing treatments for dual diagnosis: Twelve-step and self-management and recovery training. American Journal of Drug and Alcohol Abuse 2003;29(2):359-83. x-wiley/crsRef/2705182
210. Penn PE, Brooks AJ. Five years, twelve steps, and REBT in the treatment of dual diagnosis. Journal of Rational-Emotive & Cognitive-Behavior Therapy 2000;18(4):197-208. x-wiley/crsRef/2705183
211. Petersen L, Jeppesen P, Thorup A, Ohlenschlaeger J, Christensen T, Krarup G, et al. Substance abuse in first-episode schizophrenia-spectrum disorders. Schizophrenia Research 2006;86 Suppl 1:S44. x-wiley/crsRef/2705185
212. Petersen L, Jeppesen P, Thorup A, Ohlenschlaeger J, Krarup G, Ostergard T, et al. Substance abuse and first-episode schizophrenia-spectrum disorders The Danish OPUS trial. Early Intervention in Psychiatry 2007;1(1):88-96. x-wiley/crsRef/12260597
213. Petersen L, Nordentoft M, Bertelsen M, Thorup A. Does cannabis abuse determine outcome among patients with first episode psychosis. Results from the OPUS-trial. Schizophrenia Bulletin 2007;33(2):453. x-wiley/crsRef/12260598
214. Petrakis IL, Poling J, Levinson C, Nich C, Carroll C, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biological Psychiatry 2005;57(10):1128-37. x-wiley/crsRef/2705191
215. Ries RK, Dyck DG, Short R, Srebnik D, Fisher A, Comtois KA. Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatric Services 2004;55(4):445-7. x-wiley/crsRef/2705197
216. Rosenheck RA, Neale MS. Cost-effectiveness of intensive psychiatric community care for high users of inpatient services. Archives of General Psychiatry 1998;55(5):459-66. x-wiley/crsRef/2705199
217. Rowe M, Bellamy C, Baranoski M, Wieland M, O'Connell MJ, Benedict P, et al. A peer-support, group intervention to reduce substance use and criminality among persons with severe mental illness. Psychiatric Services 2007;58(7):955-61. [MEDLINE: 17602012]x-wiley/crsRef/2705201
218. Sacks S, Sacks JY, McKendrick K, Banks S, Stommel J. Modified TC for MICA offenders: crime outcomes. Behavioral Sciences and the Law 2004;22(4):477-501. x-wiley/crsRef/2705203
219. Sacks JY, Sacks S, McKendrick K, Banks S, Schoeneberger M, Hamilton Z, et al. Prison therapeutic community treatment for female offenders: profiles and preliminary findings for mental health and other variables (crime, substance use and HIV risk). Journal of Offender Rehabilitation 2008;46(3-4):233-61. x-wiley/crsRef/2705205
220. Sullivan CJ, McKendrick K, Sacks S, Banks S. Modified therapeutic community treatment for offenders with MICA disorders: substance use outcomes. American Journal of Drug and Alcohol Abuse 2007;33(6):823-32. x-wiley/crsRef/2705206
221. Sacks S, McKendrick K, Vazan P, Sacks JY, Cleland CM. Modified therapeutic community aftercare for clients triply diagnosed with HIV/AIDS and co-occurring mental and substance use disorders. AIDS Care 2011;23(12):1676-86. x-wiley/crsRef/12260600
222. Santa Ana EJ, Wulfert E, Nietert PJ. Efficacy of group motivational interviewing (GMI) for psychiatric inpatients with chemical dependence. Journal of Consulting and Clinical Psychology 2007;75(5):816-22. [MEDLINE: 17907864]x-wiley/crsRef/2705210
223. Schmitz JM, Averill P, Sayre S, McCleary P, Moeller FG, Swann A. Cognitive-behavioral treatment of bipolar disorder and substance abuse: A preliminary randomized study. Addictive Disorders and Their Treatment 2002;1(1):17-24. x-wiley/crsRef/2705214
224. Shorey RC, Martino S, Lamb KE, LaRowe SD, Santa Ana EJ. Change talk and relatedness in group motivational interviewing: a pilot study. Journal of Substance Abuse Treatment 2015;51:75-81. x-wiley/crsRef/12260602
225. Sigmon SC, Steingard S, Badger GJ, Anthony SL, Higgins ST. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study. Experimental & Clinical Psychopharmacology 2000;8(4):509-17. x-wiley/crsRef/2705216
226. Sitharthan T, Singh S, Kranitis P, Currie J, Freeman P, Murugesan G, et al. Integrated drug and alcohol intervention: development of an opportunistic intervention program to reduce alcohol and other substance use among psychiatric patients. Australian and New Zealand Journal of Psychiatry 1999;33(5):676-83. [MEDLINE: PMID 10544991]x-wiley/crsRef/2705220
227. NCT01167556. Family motivational intervention in schizophrenia. http://ClinicalTrials.gov/show/NCT01167556 2006. x-wiley/crsRef/12260604
228. Smeerdijk M, Keet R, De Haan L, Schippers G, Linszen D. Family motivation intervention in early onset psychosis and cannabis abuse: a randomized clinical trial. Proceedings of the 12th International Congress on Schizophrenia Research; 2009 Mar 28-Apr 1; San Diego, CA. Oxford Univ Press, 2009:371. x-wiley/crsRef/12260605
229. Smeerdijk M, Keet R, Dekker N, Van Raaij B, Krikke M, Koeter M, et al. Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent onset schizophrenia. Early Intervention in Psychiatry 2010;4 Suppl 1:6. x-wiley/crsRef/12260606
230. Smeerdijk M, Keet R, Dekker N, van RB, Krikke M, Koeter M, et al. Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent-onset schizophrenia: a randomized controlled trial. Psychological Medicine 2012;42(8):1627-36. x-wiley/crsRef/12260607
231. Smeerdijk M, Keet R, de Haan L, Barrowclough C, Linszen D, Schippers G. Feasibility of teaching motivational interviewing to parents of young adults with recent-onset schizophrenia and co-occurring cannabis use. Journal of Substance Abuse Treatment 2014;46(3):340-5. x-wiley/crsRef/12260608
232. Smeerdijk M, Keet R, van Raaij B, Koeter M, Linszen D, de Haan L, et al. Motivational interviewing and interaction skills training for parents of young adults with recent-onset schizophrenia and co-occurring cannabis use: 15-month follow-up. Psychological Medicine 2015;45(13):2839-48. x-wiley/crsRef/12260609
233. NCT00137267. A brief community linkage intervention for dually diagnosed individuals. https://www.ClinicalTrials.gov/ct/show/ 2005. x-wiley/crsRef/12260611
234. Smelson D, Kalman D, Losonczy MF, Kline A, Sambamoorthi U, Hill LS, et al. A brief treatment engagement intervention for individuals with co-occurring mental illness and substance use disorders: results of a randomized clinical trial. Community Mental Health Journal 2012;48(2):127-32. x-wiley/crsRef/12260612
235. Smelson DA, Losonczy MF, Ziedonis D, Sussner BD, Castles-Fonseca K, Rodrigues S, et al. A brief community linkage intervention for veterans with a persistent mental illness and a co-occurring substance abuse disorder. European Journal of Psychiatry 2012;21(2):143-52. [NCT00137267]x-wiley/crsRef/12260613
236. Cheung A, Somers JM, Moniruzzaman A, Patterson M, Frankish CJ, Krausz M, et al. Emergency department use and hospitalizations among homeless adults with substance dependence and mental disorders. Addiction Science and Clinical Practice 2015;10:17. [ISRCTN575077 and 66721740]x-wiley/crsRef/12260615
237. Noel F, Moniruzzaman A, Somers J, Frankish J, Strehlau V, Schutz C, et al. A longitudinal study of suicidal ideation among homeless, mentally ill individuals. Social Psychiatry and Psychiatric Epidemiology 2016;51(1):107-14. x-wiley/crsRef/12260616
238. Palepu A, Patterson M L, Moniruzzaman A, Frankish C J, Somers J. Housing first improves residential stability in homeless adults with concurrent substance dependence and mental disorders. American Journal of Public Health 2013;103(2 (Suppl.)):e30-36. x-wiley/crsRef/12260617
239. Rezansoff SN, Moniruzzaman A, Fazel S, McCandless L, Procyshyn R, Somers JM. Housing first improves adherence to antipsychotic medication among formerly homeless adults with schizophrenia: results of a randomized controlled trial. Schizophrenia Bulletin 2017;43(4):852-61. x-wiley/crsRef/12260618
240. Somers JM Patterson M L Moniruzzaman A Currie L Rezansoff S N Palepu A, et al. Vancouver At Home: Pragmatic randomized trials investigating Housing First for homeless and mentally ill adults. Trials 2013;14(1):365. [ISRCTN57595077]x-wiley/crsRef/12260619
241. Somers JM, Moniruzzaman A, Palepu A. Changes in daily substance use among people experiencing homelessness and mental illness: 24-month outcomes following randomization to Housing First or usual care. Addiction (Abingdon, England) 2015;110(10):1605-14. x-wiley/crsRef/12260620
242. Somers JM, Moniruzzaman A, Patterson M, Currie L, Rezansoff SN, Palepu A, et al. A randomized trial examining Housing First in Congregate and Scattered Site Formats. PLOS One 2017;12(1):e0168745. x-wiley/crsRef/12260621
243. Somers JM, Rezansoff SN, Moniruzzaman A, Palepu A, Patterson M. Housing First reduces re-offending among formerly homeless adults with mental disorders: results of a randomized controlled trial. PLOS One 2013;8(9):e72946. x-wiley/crsRef/12260622
244. Stain HJ, Bucci S, Baker AL, Carr V, Emsley R, Halpin S, et al. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: The detection and evaluation of psychological therapy (DEPTh) trial. Schizophrenia Research 2016;176(2-3):212-9. x-wiley/crsRef/12260624
245. Stain HJ, Halpin SA, Baker AL, Startup M, Carr VJ, Schall U, et al. Impact of rurality and substance use on young people at ultra high risk for psychosis. Early Intervention in Psychiatry 2018;12(6):1173-80. [DOI: 10.1111/eip.12437]x-wiley/crsRef/12260625
246. Steadman HJ, Naples M. Assessing the effectiveness of jail diversion programs for persons with serious mental illness and co-occurring substance use disorders. Behavioral Sciences and the Law 2005; Vol. 23, issue 2:163-70. x-wiley/crsRef/12260627
247. Swanson JW, Swartz MS, Borum R, Hiday VA, Wagner R, Burns BJ. Involuntary out-patient commitment and reduction of violent behaviour in persons with severe mental illness. British Journal of Psychiatry 2000;176:324-31. x-wiley/crsRef/2705226
248. ACTRN12612001059853. The effectiveness of brief-alcohol, smoking, substance involvement screening test (brief-assist) linked brief intervention (bi) for substance abuse among schizophrenic patients. http://www.anzctr.org.au/ACTRN12612001059853.aspx 2012. x-wiley/crsRef/12260629
249. Tantirangsee N, Assanangkornchai S, Marsden J. Effects of a brief intervention for substance use on tobacco smoking and family relationship functioning in schizophrenia and related psychoses: a randomised controlled trial. Journal of Substance Abuse Treatment 2015;51:30-7. x-wiley/crsRef/12260630
250. Tantirangsee N, Assanangkornchai S, Marsden J. Sy02-1the association between clinical improvement in substance-related problems and psychiatric symptoms in psychosis: a post-hoc analysis. Alcohol and Alcoholism 2014;49(Suppl. 1):i3-4. x-wiley/crsRef/12260631
251. Tantirangsee N, Assanangkornchai S, Marsden J. Sy03-1-2isam fellowship the association between clinical improvement in substance-related problems and psychiatric symptoms in psychosis: a post-hoc analysis. Alcohol and Alcoholism 2014;49(Suppl. 1):i4-5. x-wiley/crsRef/12260632
252. Teague GB, Drake RE, Ackerson TH. Evaluating use of continuous treatment teams for persons with mental illness and substance abuse. Psychiatric Services 1995;46(7):689-95. x-wiley/crsRef/2705228
253. Craig TKJ, Johnson, S, McCrone P, Afuwape S, Hughes E, Gournay K, et al. Integrated care for co-occurring disorders: psychiatric symptoms, social functioning, and service costs at 18 months. Psychiatric Services 2008;59(3):276-82. [MEDLINE: 18308908]x-wiley/crsRef/12260633
254. Hughes E, Wanigaratne S, Gournay K, Johnson S, Thornicroft G, Finch E, et al. Training in dual diagnosis interventions (the COMO Study): randomised controlled trial. BMC Psychiatry 2008;8:12. [MEDLINE: 18304310]x-wiley/crsRef/2705230
255. Johnson S, Thornicroft G, Afuwape S, Leese M, White IR, Hughes E, et al. Effects of training community staff in interventions for substance misuse in dual diagnosis patients with psychosis (COMO study): cluster randomised trial. British Journal of Psychiatry 2007;191(November):451-2. [MEDLINE: 17978327]x-wiley/crsRef/2705231
256. Thornicroft G. Prevention of admission to psychiatric hospital. A randomised controlled trial of service use, health and social care outcomes of a community mental health team intervention specific to dual diagnosis (psychosis and substance misuse) patients. http://www.controlled-trials.com. United Kingdom, 2007. x-wiley/crsRef/2705232
257. Timko C, Chen S, Sempel J, Barnett P. Dual diagnosis patients in community or hospital care: one-year outcomes and health care utilization and costs. Journal of Mental Health 2006;15(2):163-77. x-wiley/crsRef/2705234
258. Timko C, Sempel JM. Short-term outcomes of matching dual diagnosis patients' symptom severity to treatment intensity. Journal of Substance Abuse Treatment. 2004;26(3):209-18. x-wiley/crsRef/2705235
259. Ranger M, Tyrer P, Miloseska K, Fourie H, Khaleel I, North B, et al. Cost-effectiveness of nidotherapy for comorbid personality disorder and severe mental illness: randomized controlled trial. Epidemiologia e Psichiatria Sociale 2009;18(2):128-36. [MEDLINE: 19526744]x-wiley/crsRef/2705237
260. Tyrer P, Miloseska K, Whittington C, Ranger M, Khaleel I, Crawford M, et al. Nidotherapy in the treatment of substance misuse, psychosis and personality disorder: Secondary analysis of a controlled trial. Psychiatrist 2011;35(1):9-14. x-wiley/crsRef/2705238
261. Weiss RD, Griffin ML, Greenfield SF, Najavits LM, Wyner D, Soto JA, et al. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. Journal of Clinical Psychiatry 2000;61(5):361-7. x-wiley/crsRef/2705244
262. Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, et al. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. American Journal of Psychiatry 2007;164(1):100-7. x-wiley/crsRef/2705246
263. Weiss RD, Griffin ML, Jaffee WB, Bender RE, Graff FS, Gallop RJ, et al. A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial. Drug & Alcohol Dependence 2009;104(3):212-9. x-wiley/crsRef/2705248
264. Weiss, R. Modifying group therapy for bipolar substance abusers. NCT00227838. http://www.clinicaltrials.gov 2005. x-wiley/crsRef/2705249
265. Woolderink M. (Economic) Evaluation of E-mental health interventions for children of parents with mental illness (e^3 COPMI). http://www.trialregister.nl/trialreg/index.asp 2009. x-wiley/crsRef/12260636
266. Woolderink M, Bindels JA, Evers SM, Paulus AT, van Asselt AD, van Schayck OC. An online health prevention intervention for youth with addicted or mentally ill parents: experiences and perspectives of participants and providers from a randomized controlled trial. Journal of Medical Internet Research 2015;17(12):e274. [NTR 1982]x-wiley/crsRef/12260635
267. Solar A, Chamber J. A clinical study comparing more time intensive therapy with experienced alcohol and drug nurse clinicians to a Brief Information Pack for patients on a mental health unit and alcohol and drug disorders in linking to the community alcohol and drug rehabilitation service of their choice. International Clinical Trials Registry Platform 2016;1:1-2. [ACTRN126160000275460]x-wiley/crsRef/12260638
268. Gurevich GL, Agibalova TV, Rychkova OV, Buzik OZ. Pychotherapy in patients with alcohol dependence and comorbid endogenous pathology. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2015;115(4 Pt 2):28-33. x-wiley/crsRef/12260640
269. Meister K, Rietschel L, Burlon M, Jannsen H, Bock T, Wegscheider K, et al. A cluster-randomized, parallel group, observer blind trial of a group based motivational-behavioural therapy for young people with psychosis and substance use disorder. Early Intervention in Psychiatry 2010;4 Suppl 1:163. x-wiley/crsRef/2705259
270. Meister, K. Comorbid psychosis and addiction. Epidemiology, explanatory models and evaluation of motivational behavioural group therapy [Komorbidität psychose und sucht. Epidemiologie, erklärungsmodelle und evaluation einer motivational-verhaltenstherapeutischen gruppentherapie]. Dissertation, University of Hamburg 2010. x-wiley/crsRef/2705260
271. NCT01883791. Screening, Brief Intervention and Referral to Treatment for substance abuse in mental health treatment settings (SBIRT in MH). https://ClinicalTrials.gov/show/NCT01883791 2017. x-wiley/crsRef/12260642
272. Spear SE, Karno M, Glasner-Edwards S, Rawson R, Saitz R, Dominguez B. Applying SBIRT to new settings: Preliminary findings of substance use disorder risk in community mental health settings. Drug and Alcohol Dependence 2015;156:e209. x-wiley/crsRef/12260643
273. NCT02214667. Treating co-occurring substance use and mental disorders among jail inmates. http://Clinicaltrials.gov/show/NCT02214667 2015. x-wiley/crsRef/12260645
274. Van Dorn RA, Desmarais SL, Rade CB, Burris EN, Cuddeback GS, Johnson KL, et al. Jail-to-community treatment continuum for adults with co-occurring substance use and mental disorders: study protocol for a pilot randomized controlled trial. Trials 2017;18(1):365. x-wiley/crsRef/12260646
275. Gonzalez-Ortega I, Echeburua E, Garcia-Alocen A, Vega P, Gonzalez-Pinto A. Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial. Trials 2016;17:372. x-wiley/crsRef/12260648
276. NCT02319746. Cognitive behavioral therapy program to first-episode psychosis patients and cannabis abuse. https://Clinicaltrials.gov/ct2/show/NCT02319746 2014. x-wiley/crsRef/12260649
277. NCT02670902. Intervention for persons leaving residential substance abuse treatment. https://ClinicalTrials.gov/show/NCT02670902 2016. x-wiley/crsRef/12260651
278. NCT03007940. Using NIATx strategies to implementiIntegrated services in routine care. https://ClinicalTrials.gov/show/NCT03007940 2016. x-wiley/crsRef/12260653
279. Bennett M, Bellack AS, Dixon L. Treatment of alcohol use disorders in people with severe mental illness. Schizophrenia Bulletin 2007;33(2):421. x-wiley/crsRef/2705266
280. NCT00280813. Treatment of alcohol use disorders in schizophrenia. http://www.clinicaltrials.gov 2006. x-wiley/crsRef/2705267
281. ISRCTN33576045. Contingency intervention for reduction of cannabis in early psychosis -circle. http://www.controlled-trials.com 2011. x-wiley/crsRef/12260655
282. ISRCTN33576045. Randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention for reduction of cannabis use and of relapse in early psychosis. Circle. http://public.ukcrn.org.uk/ 2012. x-wiley/crsRef/12260656
283. Johnson S, Sheridan Rains L, Marwaha S, Strang J, Craig T, Weaver T, et al. A randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention compared to treatment as usual for reduction of cannabis use and of relapse in early psychosis (CIRCLE): a study protocol for a randomised controlled trial. Trials 2016;17(1):515. x-wiley/crsRef/12260657
284. NCT00783185. Dual diagnosis (psychosis and cannabis misuse): comparison of specialized treatment versus unspecified treatment. http://www.clinicaltrials.gov 2008. x-wiley/crsRef/2705275
285. NCT00798109. Effect of motivational therapy on schizophrenia with cannabis misuse. http://www.clinicaltrials.gov 2008. x-wiley/crsRef/2705277
286. Verstappen N, Henquet C. Effects and indicators of CBT for cannabis use in psychosis [Studie naar 'Behandeling cananbisgebruik en psychose']. http://www.trialregister.nl/trialreg/index.asp 2007. x-wiley/crsRef/2705287
287. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research 1992;6(3):201-8.
288. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200. [TP020600]
289. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trial: explanation and elaboration. Annals of Internal Medicine 2001;134(8):663-94.
290. Andreasen NC. Negative symptoms in schizophrenia. Archives of General Psychiatry 1982;39:784-8.
291. Appleby L, Dyson V, Altman E, Luchins DJ. Assessing substance use in multiproblem patients: reliability and validity of the Addiction Severity Index in a mental hospital population. Journal of Nervous & Mental Disease 1997;185(3):159-65.
292. Asberg M, Montgomery SA, Perris C, et al. A comprehensive psychopathological rating scale. Acta Psychiatrica Scandinavica Supplement 1978;271:5-27.
293. Baandrup L, Østrup Rasmussen J, Klokker L, Austin S, Bjornshave T, Fuglsang Bliksted V, et al. Treatment of adult patients with schizophrenia and complex mental health needs-A national clinical guideline. Nordic Journal of Psychiatry 2016;70(3):231-40.
294. Baker AL, Hiles SA, Thornton LK, Hides L, Lubman DI. A systematic review of psychological interventions for excessive alcohol consumption among people with psychotic disorders. Acta Psychiatrica Scandinavica 2012;126(4):243-55.
295. Barrowclough C, Haddock G, Fitzsimmons M, Johnson R. Treatment development for psychosis and co-occurring substance misuse: A descriptive review. Journal of Mental Health 2006;15(6):619-32.
296. Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technique. Postgraduate Medicine 1972;52(6):81-5.
297. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9.
298. Bennett ME, Bradshaw KR, Catalano LT. Treatment of substance use disorders in schizophrenia. American Journal of Drug & Alcohol Abuse 2017;43(4):377-90.
299. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale: the development and validation of a scale of social adjustment for use in family intervention programmes with schizophrenic patients. British Journal of Psychiatry 1990;157(December):853-9.
300. Bland JM, Kerry SM. Trials randomised in clusters. BMJ 1997;315(7108):600.
301. Bogenschutz MP, Geppert CM, George J. The role of twelve-step approaches in dual diagnosis treatment and recovery. American Journal on Addictions 2006;15(1):50-60.
302. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
303. Bond GR, Miller LD, Krumwied RD, Ward RS. Assertive case management in three CMHCs: a controlled study. Hospital and Community Psychiatry 1988;39(4):411-8.
304. Bond GR, Witheridge TF, Dincin J, Wasmer D, Webb J, DeGraaf-Kaser R. Assertive community treatment for frequent users of psychiatric hospitals in a large city: a controlled study. American Journal of Community Psychology 1990;18(6):865-91.
305. Bond GR, Drake RE. The critical ingredients of assertive community treatment. World Psychiatry 2015;14(2):240-2.
306. Bond GR, Drake RE. New directions for psychiatric rehabilitation in the USA. Epidemiology & Psychiatric Science 2017;26(3):223-7.
307. Boniface S, Malet-Lambert I, Coleman R, Deluca P, Donoghue K, Drummond C, et al. The effect of brief interventions for alcohol among people with comorbid mental health conditions: A systematic review of randomized trials and narrative synthesis. Alcohol & Alcoholism 2018;53(3):282-93.
308. Brunette MF, Mueser KT, Babbin S, Meyer-Kalos P, Rosenheck R, Correll CU, et al. Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophrenia Research 2018;194:4-12.
309. Burns T, Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatrica Scandinavica 2007;116(6):403-18.
310. Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. American Journal of Psychiatry 2012;169(4):389-96.
311. Carey KB, Cocco KM, Simons JS. Concurrent validity of clinicians' rating of substance abuse among psychiatric outpatients. Psychiatric Services 1996;47(8):842-7.
312. Carra G, Johnson S. Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review. Social Psychiatry & Psychiatric Epidemiology 2009;44(6):429-47.
313. Chanut F, Brown TG, Dongier M. Motivational interviewing and clinical psychiatry. Canadian Journal of Psychiatry 2005;50(9):548-54.
314. Cleary M, Hunt GE, Matheson S, Walter G. Psychosocial treatments for people with co-occurring severe mental illness and substance misuse: systematic review. Journal of Advanced Nursing 2009;65(2):238-58.
315. Cleary M, Hunt GE, Horsfall J. Conducting efficient literature searches. Strategies for mental health nurses. Journal of Psychosocial Nursing & Mental Health Services 2009;47(11):34-41.
316. Corse SJ, Hirschinger NB, Zanis D. The use of the Addiction Severity Index with people with severe mental illness. Psychiatric Rehabilitation Journal 1995;19(1):9-18.
317. Crockford D, Addington D. Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders. Canadian Journal of Psychiatry 2017;62(9):624-34.
318. Darke S, Ward J, Hall W, Heather N, Wodak A. The Opiate Treatment Index (OTI) Researchers Manual. Technical report No. 11. Sydney: National Drug & Alcohol Research Centre, 1991.
319. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. British Journal of Addiction 1992;87(5):733-42.
320. David A, Buchanan A, Reed A, Almeida O. The assessment of insight in psychosis. British Journal of Psychiatry 1992;161(November):599-602.
321. De Witte NA, Crunelle CL, Sabbe B, Moggi F, Dom G. Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review. European Addiction Research 2014;20(3):105-14.
322. Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
323. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
324. Derogatis LR, Lipman RS, Covi L. SCL-90: An outpatient psychiatric rating scale: Preliminary report. Psychopharmacology Bulletin 1973;9(1):13-27.
325. Derogatis LR, Yevzeroff H, Wittelsberger B. Social class, psychological disorder, and the nature of the psych0pathologic indicator. Journal of Consulting and Clinical Psychology 1975;43(2):183-91.
326. Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory report. Psychological Medicine 1983;13(3):595-605.
327. Derogatis LR. SCL-90-R: Administration, Scoring & Procedures Manual-II. Towson, MD: Clinical Psychometric Research, 1983.
328. Dieterich M, Irving CB, Bergman H, Khokhar MA, Park B, Marshall M. Intensive case management for severe mental illness. Cochrane Database of Systematic Reviews 2017;1:CD007906. [DOI: 10.1002/14651858.CD007906.pub3]
329. Divine GW, Brown JT, Frazer LM. The unit analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
330. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, et al. The 2009 schizophrenia PORTpsychosocial treatment recommendations and summary statements. Schizophrenia Bulletin 2010;36(1):48-70.
331. Dohrenwend BP, Shrout PE, Egri G, et al. Nonspecific psychological distress and other dimensions of psychopathology. Measures for use in the general population. Archives of General Psychiatry 1980;37(11):1229-36.
332. Donald M, Downer J, Kavanagh D. Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomised controlled trials. Social Science and Medicine 2005;60(6):1371-83.
333. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
334. Drake RE, Bartels SJ, Teague GB, Noordsy DL, Clark RE. Treatment of substance abuse in severely mentally ill patients. Journal of Nervous and Mental Disease 1993;181(10):606-11.
335. Drake RE, Mueser KT, Clarke RE, Wallach MA. The course, treatment, and outcome of substance disorder in persons with severe mental illness. American Journal of Orthopsychiatry 1996;66(1):42-51.
336. Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. A review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophrenia Bulletin 1998;24(4):589-608.
337. Drake RE, Mueser KT, Brunette MF, McHugo GJ. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatric Rehabilitation Journal 2004;27(4):360-74.
338. Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse and Treatment 2008;34(1):123-38.
339. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (DSM III-R). Diagnostic & Statistical Manual of Mental Disorders (DSM III-R). 3rd Edition. Washington D.C: American Psychiatric Association, 1987.
340. APA 1994. Diagnostic & Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: APA, 1994.
341. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. American Journal of Psychiatry 2008;165(2):179-87.
342. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
343. Elbourne D, Altman DG, Higgins JP, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
344. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976;33(6):766-71.
345. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
346. Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 2016;50(5):410-72.
347. Goldman HH, Skodal AE, Lave TR. Revising Axis V for DSM-IV: a review of measures of social functioning. Americal Journal of Psychiatry 1992;149(9):1148-56.
348. Green RS, Gracely EJ. Selecting a rating scale for evaluating services to the chronically mentally ill. Community Mental Health Journal 1987;23(2):91-102.
349. Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. Americal Journal of Psychiatry 2007;164(3):402-8.
350. Gregg L, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis. Clinical Psychology Review 2007;27(4):494-510.
351. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83.
352. Haddock G, Eisner E, Boone C, Davies G, Coogan C, Barrowclough C. An investigation of the implementation of NICE-recommended CBT interventions for people with schizophrenia. Journal of Mental Health 2014;23(4):162-5.
353. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23(February):56-62.
354. Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;71(3):248-54.
355. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World Journal of Biological Psychiatry 2015;16(3):142-70.
356. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
357. Higgins JP, Green S (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
358. Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
359. Hjorthoj C, Fohlmann A, Nordentoft M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review. Addictive Behaviors 2009;34(6-7):520-5.
360. Hodgins DC, el-Guebaly N. More data on the Addiction Severity Index. Reliability and validity with the mentally ill substance abuser. Journal of Nervous & Mental Disease 1992;180(3):197-201.
361. Horn JL, Wanberg KW, Foster FM. The Alcohol Use Inventory. Minneapolis, MN: National Computer Systems, 1987.
362. Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harvard Review of Psychiatry 2009;17(1):24-34.
363. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophrenia Research 2002;54(3):253-64.
364. Hunt GE, Malhi GS, Cleary M, Lai HMX, Sitharthan T. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis. Journal of Affective Disorders 2016;206:331-49.
365. Hunt GE, Large M, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug and Alcohol Dependence 2018;191:234-58.
366. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
367. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organization, 1992.
368. Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behaviour therapy for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD000524]
369. Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD008712.pub2]
370. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis - linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research 2005;79:59-68.
371. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
372. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-76.
373. Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addictive Behaviors 2012;37(1):11-24.
374. Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophrenia Research 2018;194:78-85.
375. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010;35(1):217-38.
376. Lai HM, Sitharthan T, Huang QR. Exploration of the comorbidity of alcohol use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. Substance Abuse 2012;33(2):138-45.
377. Lai HM, Sitharthan T. Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. American Journal of Drug & Alcohol Abuse 2012;38(6):567-74.
378. Lai HM, Cleary M, Sitharthan T, Hunt GE. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: A systematic review and meta-analysis. Drug and Alcohol Dependence 2015;154:1-13.
379. Lappin JM, Roxburgh A, Kaye S, Chalmers J, Sara G, Dobbins T, et al. Increased prevalence of self-reported psychotic illness predicted by crystal methamphetamine use: Evidence from a high-risk population. International Journal of Drug Policy 2016;38:16-20.
380. Large M, Mullin K, Gupta P, Harris A, Nielssen O. Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Australian & New Zealand Journal of Psychiatry 2014;48(5):418-32.
381. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Evaluation and Program Planning 1979;2(2):197-207.
382. LeDuc PA, Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology 1995;121:407-27.
383. Lehman AF. A quality of life interview for the chronically mentally ill. Evaluation and Program Planning 1988;11(1):51-62.
384. Lehman AF. Evaluating Quality of Life for Persons with Severe Mental Ilness: Assessment Toolkit. Cambridge, Mass: The Evaluation Center at Health Services Research Institute, 1995.
385. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]
386. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187(October):366-71. [PUBMED: 16199797]
387. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
388. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
389. Lowe AL, Abou-Saleh MT. The British experience of dual diagnosis in the national health service. Acta Neuropsychiatrica 2004;16(1):41-6.
390. Lubman DI, King JA, Castle DJ. Treating comorbid substance use disorders in schizophrenia. International Review of Psychiatry 2010;22(2):191-201.
391. Lukoff D, Nuechterlein KH, Ventura J. Manual for expanded Brief Psychiatric Rating Scale (BPRS). Schizophrenia Bulletin 1986;12(4):594-602.
392. Marshall M, Gray A, Lockwood A, Green R. Case management for people with severe mental disorders. Cochrane Database of Systematic Reviews 1998, Issue 2. [DOI: 10.1002/14651858.CD000050]
393. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176(March):249-52.
394. Mas-Exposito L, Amador-Campos JA, Gomez-Benito J, Mauri-Mas L, Lalucat-Jo L. Clinical case management for patients with schizophrenia with high care needs. Community Mental Health Journal 2015;51(2):165-70.
395. McHugo GJ, Drake RE, Burton HL, Ackerson TH. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. Journal of Nervous and Mental Disease 1995;183(12):762-7.
396. McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry 2013;70(3):319-24.
397. McLellan AT, Luborsky L, Woody GE, O'Brien C. An improved evaluation instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous and Mental Disease 1980;168(1):26-33.
398. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992;9(3):199-213.
399. Mihalopoulos C, McGorry PD, Carter RC. Is phase-specific community -oriented treatment of early psychosis an economically viable method of improving outcome?. Acta Psychiatrica Scandinavica 1999;100(1):47-55.
400. Miller WR, Marlatt AG. Brief Drinker Profile (BDP) Interview Booklet. Odessa, FL: Psychological Assessment Resources, Inc, 1987.
401. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
402. Montgomery SA, Asberg M, Taylor P, Montgomery D. Development of a schizophrenia scale sensitive to change. Neuropharmacology 1978;17(12):1061-3.
403. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134(April):382-9.
404. Morgan VA, Waterreus A, Carr V, Castle D, Cohen M, Harvey C, et al. Responding to challenges for people with psychotic illness: Updated evidence from the Survey of High Impact Psychosis. Australian & New Zealand Journal of Psychiatry 2017;51(2):124-40.
405. Mueser KT, Drake RE, Clark RE, McHugo GJ, Mercer-McFadden C, Ackerson TH. Evaluating Substance Abuse in Persons with Severe Mental Illness. Cambridge, MA: Human Services Research Institute, 1995.
406. Mueser KT. Clinical interventions for severe mental illness and co-occurring substance use disorder. Acta Neuropsychiatrica 2004;16(1):26-35.
407. Mueser KT, Drake RE, Sigmon SC, Brunette MF. Psychosocial interventions of adults with severe mental illnesses and co-occurring substance use disorders: a review of specific interventions. Journal of Dual Diagnosis 2005;1(2):57-82.
408. Mueser KT, Deavers F, Penn DL, Cassisi JE. Psychosocial treatments for schizophrenia. Annual Review of Clinical Psychology 2013;9:465-97.
409. Murthy P, Chand P. Treatment of dual diagnosis disorders. Current Opinion in Psychiatry 2012;25(3):194-200.
410. NICE. Psychosis with coexisting substance misuse. Assessment and management in adults and young people. National Clinical Guideline 120. London: British Psychological Society and the Royal College of Psychiatrists, 2011:1-322. [http://www.nice.org.uk/CG120]
411. Norman RM, Malla AK, Cortese L, Diaz F. A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophrenia Research 1996;19(1):73-85.
412. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10(3):799-812.
413. Pettersen H, Ruud T, Ravndal E, Havnes I, Landheim A. Engagement in assertive community treatment as experienced by recovering clients with severe mental illness and concurrent substance use. International Journal of Mental Health Systems 2014;8(1):40.
414. Pluddemann A, Dada S, Parry CD, Kader R, Parker JS, Temmingh H, et al. Monitoring the prevalence of methamphetamine-related presentations at psychiatric hospitals in Cape Town, South Africa. African Journal of Psychiatry 2013;16(1):45-9.
415. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). International Journal of Social Psychiatry 1999;45(1):7-12.
416. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. Journal of Nervous & Mental Disease 2012;200(10):832-9.
417. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264(19):2511-8.
418. Rollnick S, Heather N, Gold R, Hall W. Development of a short 'readiness to change' questionnaire for use in brief opportunistic interventions among excessive drinkers. British Journal of Addiction 1992;87(5):743-54.
419. Romer Thomsen K, Thylstrup B, Pedersen MM, Pedersen MU, Simonsen E, Hesse M. Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders. Schizophrenia Research 2018;195:495-500.
420. Sara GE, Large MM, Matheson SL, Burgess PM, Malhi GS, Whiteford HA, et al. Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. Australian & New Zealand Journal of Psychiatry 2015;49(2):106-17.
421. Saunders JB, Aasland OG, Babor TF de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction 1993;88(6):791-804.
422. Schmidt LM, HesseM, Lykke J. The impact of substance use disorders on the course of schizophrenia - a 15-year follow-up study: dual diagnosis over 15 years. Schizophrenia Research 2011;130(1-3):228-33.
423. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
424. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
425. Seibyl JP, Satel SL, Dominic A, Southwick SM, Krystal JH, Charney DS. Effects of cocaine on hospital course in schizophrenia. Journal of Nervous and Mental Disease 1993;181(1):30-7.
426. Seivewright N, McMahon C, Egleston P. Stimulant use still going strong: revisiting..misuse of amphetamines and related drugs. Advances in Psychiatric Treatment 2005;11(July):262-9.
427. Shokraneh F, Adams CE. Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis. BioImpacts 2017;7(4):209-17. [DOI: 10.15171/bi.2017.25]
428. Siegfried N. A review of comorbidity: major mental illness and problematic substance use. Australian and New Zealand Journal of Psychiatry 1998;32(5):707-17.
429. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Quality of Life Research 2004;13(2):299-310.
430. Spitzer RL, Williams JB, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R - Patient Edition (SCID-P). Washington, DC: American Psychiatric Press, 1990.
431. Stein LI, Test MA. Alternative to mental hospital treatment: 1 Conceptual model, treatment program, and clinical evaluation. Archives of General Psychiatry 1980;37(4):392-7.
432. Sterne JA, Egger M, Moher D (editors) on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
433. Thoma N, Pilecki B, McKay D. Contemporary cognitive behavior therapy: A review of theory, history, and evidence. Psychodynamic Psychiatry 2015;43(3):423-62.
434. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophrenia Research 2000;42(3):240-7.
435. Tiet QQ, Mausbach B. Treatment for patients with dual diagnosis: a review. Alcoholism: Clinical and Experimental Research 2007;31(4):513-36.
436. Todd J, Green G, Harrison M, Ikuesan BA, Self C, Baldacchino A, et al. Defining dual diagnosis of mental illness and substance misuse: some methodological issues. Journal of Psychiatric and Mental Health Nursing 2004;11(1):48-54.
437. Tsuang J, Fong TW, Lesser I. Psychosocial treatment of patients with schizophrenia and substance abuse disorders. Addictive Disorders and Their Treatment 2006;5(2):53-66.
438. Turpin DL. CONSORT and QUOROM guidelines for reporting randomized clinical trials and systematic reviews. American Journal of Orthodontics and Dentofacial Orthodapedics 2005;128(6):681-6.
439. Tyrer P, Owen RT, Cicchetti DV. The brief scale for anxiety: a subdivision of the Comprehensive Psychopathological Rating Scale. Journal of Neurology, Neurosurgery and Psychiatry 1984;47(9):970-5.
440. Tyrer P, Weaver T. Desperately seeking solutions: the search for appropriate treatment for comorbid substance misuse and psychosis. Psychiatric Bulletin 2004;28(1):1-2.
441. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317]
442. Warren JI, Stein JA, Grella CE. Role of social support and self-efficacy in treatment outcomes among clients with co-occurring disorders. Drug and Alcohol Dependence. 2007;89(2-3):267-74.
443. Wieduwilt KM, Jerrell JM. The reliability and validity of the SAS-SMI. Journal of Psychiatric Research 1999;33(2):105-12.
444. Wing JK, Babor T, Brugha T, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 1990;47(6):589-93.
445. Wing JK, Curtis R, Beevor A. The Health of the Nation Outcome Scales. London: Royal College of Psychiatrists, 1996.
446. Work Group on Substance Use Disorders, Kleber HD, Weiss RD, Anton RF, Rounsaville BJ, George TP, Strain EC, et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Americal Journal of Psychiatry 2007;164 Suppl:5-123.
447. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
448. Young RC, Briggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 1978;133(November):429-35.
449. Zanis DA, McLellan AT, Corse S. Is the Addiction Severity Index a reliable and valid assessment instrument among clients with severe and persistent mental illness and substance abuse disorders?. Community Mental Health Journal 1997;33(3):213-27.
450. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. Journal of Psychiatric Practice 2005;11(5):315-39.
451. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 1983;67(6):361-70.
452. Cleary M, Hunt GE, Matheson SL, Siegfried N, Walter G. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD001088.pub2]
453. Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD001088.pub3]
454. Ley A, Jeffery DP, McLaren S, Siegfried N. Treatment programmes for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001088]